COVID-19 and Diabetes

A special issue of Diabetology (ISSN 2673-4540).

Deadline for manuscript submissions: closed (10 August 2021) | Viewed by 978

Special Issue Editors

Baker Heart and Diabetes Institute, Atherothrombosis and Vascular Biology, Melbourne, Australia
Interests: atherothrombosis and unstable atherosclerotic plaque; urine proteomics; micro-RNA for anti-atherosclerotic therapy; gut microbiome; single cell RNA-seq; animal model
Special Issues, Collections and Topics in MDPI journals
Baker Heart and Diabetes Institute, Atherothrombosis and Vascular Biology, Melbourne, Australia; Baker Department of Cardiometabolic Health, University of Melbourne, Australia; Department of Clinical Haematology, Alfred Hospital, Melbourne, Australia; Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia
Interests: coagulation pathway; platelets; stroke; thrombosis; myocardial infarction; antithrombotics; anti-coagulants; venous thrombosis

Special Issue Information

Dear Colleagues,

It has been nearly one year since the COVID-19 outbreak. With over 87 million infected and 1.8 million deaths worldwide, many countries are still in the grip of a public health emergency and are experiencing significant social disruptions and health care systems are under considerable strain. We now know that approximately 10% of patients with COVID-19 can suffer from "long-COVID" symptoms, which can manifest with headache, chronic fatigue, difficulty breathing, myalgia, and dysphonia that can last for 1 to 6 months. Significantly, it has emerged that patients with pre-existing health conditions, such as cardiovascular disease, diabetes, and hypertension, are more vulnerable to the effects of COVID-19 infection. Indeed, patients with diabetes and COVID-19 infection have a 7.3% higher risk of death compared to those without diabetes. The high blood glucose level with constant systematic inflammation could attribute to the high-risk profile of COVID-19 mortality. Therefore, further research regarding the mechanistic links between diabetes and adverse COVID-19 clinical outcomes is of paramount importance.

Dr. Yung-Chih Chen
Dr. James McFadyen
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diabetology is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Type 1 diabetes
  • Type 2 diabetes
  • gestational diabetes
  • hyperglycemia
  • insulin resistance
  • renal failure
  • clinical management
  • pathogenesis
  • chronic inflammation
  • angiotensin receptor

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop